Christoph Reich

Dr. Christoph Reich

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
LNLuka Nicin
Luka Nicin
SSSam Michael Schroeter
Sam Michael Schroeter
SGSimone-Franziska Glaser
Simone-Franziska Glaser
RSRalf Schulze-Brüning
Ralf Schulze-Brüning
MPMinh-Duc Pham
Minh-Duc Pham
DBDittmar Böckler
Dittmar Böckler
Pathological cardiac hypertrophy is a leading cause of heart failure, but knowledge of the full repertoire of cardiac cells and their gene expression profiles in the human hypertrophic heart is missing. Here, by using large-scale single-nucleus transcriptomics, we present the transcriptional response of human cardiomyocytes to pressure overload caused by aortic valve stenosis and describe major alterations in cardiac cellular crosstalk. Hypertrophied cardiomyocytes had reduced input from endothelial cells and fibroblasts. Genes encoding Eph receptor tyrosine kinases, particularly EPHB1, were significantly downregulated in cardiomyocytes of the hypertrophied heart. Consequently, EPHB1 activation by its ligand ephrin (EFN)B2, which is mainly expressed by endothelial cells, was reduced. EFNB2 inhibited cardiomyocyte hypertrophy in vitro, while silencing its expression in endothelial cells induced hypertrophy in co-cultured cardiomyocytes. Our human cell atlas of the hypertrophied heart highlights the importance of intercellular crosstalk in disease pathogenesis and provides a valuable resource.

22 November 2024 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
RWReto Wettstein
Reto Wettstein
Farbod Sedaghat-HamedaniFarbod Sedaghat-Hamedani
Farbod Sedaghat-Hamedani
OHOliver Heinze
Oliver Heinze
AAAli Amr
Ali Amr
CRChristoph Reich
Christoph Reich
Benjamin MederBenjamin Meder
Benjamin Meder
Background: Technological advances allow for recording and sharing health-related data in a patient-centric way using smartphones and wearables. Secure sharing of such patient-generated data with physicians would enable close management of individual health trajectories, monitoring of risk factors, and asynchronous feedback. However, most remote patient monitoring (RPM) systems currently available are not fully integrated into hospital IT systems or lack a patient-centric design. Objective: The objective of this study was to conceptualize and implement a user-friendly, reusable, interoperable, and secure RPM system incorporating asynchronous feedback mechanisms using a broadly available consumer wearable (Apple Watch). In addition, this study sought to evaluate factors influencing patient acceptance of such systems. Methods: The RPM system requirements were established through focus group sessions. Subsequently, a system concept was designed and implemented using an iterative approach ensuring technical feasibility from the beginning. To assess clinical feasibility, the system was used as part of the activeDCM prospective randomized interventional study focusing on dilated cardiomyopathy. Each patient used the system for at least 12 months. The System Usability Scale was used to measure usability from a subjective patient perspective. In addition, an evaluation was conducted on the objective wearable interaction frequency as well as the completeness of transmitted data classified into sensor-based health data (SHD) and patient-reported outcome measures (PROMs). Descriptive statistics using box plots and bootstrapped multiple linear regression with 95% CIs were used for evaluation analyzing the influence of age, sex, device experience, and intervention group membership. Results: The RPM system comprised 4 interoperable components: patient devices, a data server, a data viewer, and a notification service. The system was evaluated with 95 consecutive patients with dilated cardiomyopathy (28/95, 29% female; mean age 50, SD 12 y) who completed the activeDCM study protocol. The system’s app achieved a mean System Usability Scale score of 78 (SD 17), which was most influenced by device experience. In total, 87% (83/95) of the patients could integrate the use of the app well or very well into their daily routine, and 71% (67/95) saw a benefit of the RPM system for management of their health condition. On average, patients interacted with the wearable on 61% (SD 26%) of days enrolled in the study. SHD were available on average for 78% (SD 23%) of days, and PROM data were available on 64% (SD 27%) of weeks enrolled in the study. Wearable interaction frequency, SHD, and PROM completeness were most influenced by intervention group membership. Conclusions: Our results mark a first step toward integrating RPM systems based on a consumer wearable device for primary patient input into standardized clinical workflows. They can serve as a blueprint for creating a user-friendly, reusable, interoperable, and secure RPM system that can be integrated into patients’ daily routines.

13 January 2026 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JHJan Haas
Jan Haas
SSSarah Schudy
Sarah Schudy
BRBenedikt Rauscher
Benedikt Rauscher
AVAna Muñoz Verdú
Ana Muñoz Verdú
SRSteffen Roßkopf
Steffen Roßkopf
Benjamin MederBenjamin Meder
Benjamin Meder
Dysregulation of alternative splicing – mediated by factors such as RBM20 or SLM2 – can affect proper gene isoform control, disrupting gene isoform homeostasis and underpins severe cardiomyopathy in both animal models and patients. Although innovative therapies target various sarcomeric components, the impact of isoform switching in cardiac disease remains poorly understood. Here, we applied nanopore long-read sequencing to map the full-length transcriptome of left ventricular tissue from thirteen nonfailing controls, ten patients with dilated cardiomyopathy (DCM), and ten with ischemic cardiomyopathy (ICM). Our analysis identified 78,520 transcripts, 31% of which represent novel isoforms of known genes. Notably, the transcriptomes of DCM and ICM were largely indistinguishable, indicating that end-stage heart failure is characterized by a convergent isoform landscape, irrespective of disease etiology. Among 11 prototypical sarcomere genes, 10 displayed highly significant isoform shifts (p = 5.23 × 10 −45 –2.89 × 10 −200 ). Focusing on tropomyosin, we observed that while the predominant cardiac gene TPM1 showed moderate up-regulation of its transcript isoforms, transcripts derived from TPM3 —typically expressed at lower levels in the healthy heart—were markedly increased in heart failure.

10 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Elham KayvanpourElham Kayvanpour
Elham Kayvanpour
EMElena Matzeit
Elena Matzeit
CRChristoph Reich
Christoph Reich
ZKZiya Kaya
Ziya Kaya
SPSven Pleger
Sven Pleger
Farbod Sedaghat-HamedaniFarbod Sedaghat-Hamedani
Farbod Sedaghat-Hamedani
Background: Atrial septal defect (ASD) is a prevalent congenital heart condition, resulting in left-to-right shunting. Untreated ASDs may be associated with complications, including right-sided heart failure, pulmonary hypertension, and atrial arrhythmias. Percutaneous ASD closure, performed with various occluder devices, has become the preferred approach for symptomatic patients with suitable anatomy, yet data on device-specific efficacy and safety profiles remain limited. Methods: This study was a retrospective, single-center analysis involving patients who underwent percutaneous ASD closure between January 2000 and February 2023. Data on patient characteristics, indications for the procedure, procedural details, and clinical outcomes were extracted from electronic medical records. Endpoints included complications at the puncture site, pericardial effusion, atrial arrhythmias, device-related thrombus formation, and overall survival. Results: A total of 195 patients were included (mean age 53.6 ± 16.2 years; 60.5% female). Three different devices were used: Amplatzer ASD occluder (n = 111), Gore Septal Occluder (n = 67), and Occlutech ASD occluder (n = 17). Initial procedural success rate was 90.8%, with no significant differences observed between devices. Periprocedural complication rates were low and comparable across all devices. New-onset atrial fibrillation within the first month post-implantation occurred in 7.5% of patients with the Gore device, compared to 0.9% with the Amplatzer device (p = 0.03) and 0% with the Occlutech device. No statistically significant differences were observed among the devices regarding thrombus formation, late-onset pericardial effusion, device erosion, or stroke. Conclusions: Percutaneous ASD closure demonstrates high procedural success and low complication rates across different occluder devices, supporting its efficacy and safety as a treatment for adults. Although the Gore device showed a higher incidence of new-onset AF compared to the Amplatzer device, no significant differences were observed regarding thrombus formation, pericardial effusion, device erosion or stroke.

10 March 2021 in Der Kardiologe
Verified
Journal Article
Open access
PDF file
CRChristoph Reich
Christoph Reich
Benjamin MederBenjamin Meder
Benjamin Meder
Neue digitale Technologien bieten großes Potenzial, die Gesundheitsversorgung in den kommenden Jahrzehnten grundlegend zu verändern. Die „Digital Health“ umfasst dabei nahezu alle Bereiche im Gesundheitssystem und nimmt – nicht nur wegen der aktuellen COVID-19-Pandemie – erheblich an Bedeutung zu. In Zukunft sollen nicht nur bekannte Prozesse digitalisiert werden, sondern neue digitale Maßnahmen eine Beteiligung des Patienten gezielt fördern und ihn aktiv in Diagnose- sowie Behandlungsprozess einbinden. Der „e-Patient“ erhält damit in Zukunft durch Smart Devices und Direct-to-Consumer-Technologien einen erleichterten Zugang zu seinen eigenen Gesundheitsdaten, die bisher in Datensilos aufbewahrt und nur eingeschränkt an ihn weitergegeben werden. Fortschritte in der Sensortechnologie und bei sog. Wearables ermöglichen nicht nur ein kontinuierliches Monitoring und einen Beitrag zu diesen patientenzentrierten Gesundheitsdaten, sondern ermöglichen neue Diagnoseverfahren und Therapien außerhalb des Krankenhauses. Die Digitalisierung liefert also zahlreiche Ansätze für eine effizientere und kostengünstigere Krankenversorgung und Prävention.

1 January 2025 in Open Heart
Verified
Journal Article
Open access
PDF file
CRChristoph Reich
Christoph Reich
MYMustafa Yildirim
Mustafa Yildirim
CSChristian Salbach
Christian Salbach
MBMoritz Biener
Moritz Biener
PAPedro Lopez Ayala
Pedro Lopez Ayala
EGEvangelos Giannitsis
Evangelos Giannitsis
Background: High-sensitivity cardiac troponin tests have enhanced early myocardial infarction diagnosis, yet many patients still land in the observe zone (OZ). Guidelines suggest a 3-hour troponin measurement for those in the European Society of Cardiology (ESC) 0/1 hour-algorithm’s OZ, but evidence on extended troponin testing times and their impact on diagnostic accuracy and outcomes remains sparse. Methods: Patients with suspected acute coronary syndrome were consecutively enrolled in a single-centre observational study. The triage protocol allowed an optional third troponin measurement at 3 hours or later to evaluate the performance and safety of two validated triage algorithms used to resolve the OZ. Results: Of the 4605 patients, 948 were triaged to the OZ (20.6%). The prevalence of non-ST-segment elevation myocardial infarction (NSTEMI) within the OZ was 7.2%. 212 patients (22.3% of OZ patients) had a third troponin measurement and were included in the comparative analysis. For diagnosing NSTEMI, the ESC 0/3-hour criteria showed lower sensitivity (69.4%) than the criteria defined in the Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) study (86.1%, p=0.053), with both having high negative predictive value (93.5% vs 87.5%, p=0.339). By definition, the ESC 0/3-hour algorithm categorises all patients into rule-in or rule-out, eliminating the need for an OZ, whereas 55.6% of patients remained in the OZ with the APACE criteria. Mortality rates in the OZ were similar across different timing protocols, with 30-day rates of 0.78% for third blood draws within 210 min (n=128) and 1.19% for those over 210 min (n=84); 3-year rates were 5.51% and 4.82%, confirming the safety of extended sampling. Conclusions: Although the ESC 0/3-hour criteria have a lower sensitivity than the APACE criteria, it is by definition more effective because it does not leave patients in the OZ. Extending the timing for the third troponin measurement beyond 3 hours proves to be effective and safe, supporting its implementation in clinical practice. Trial registration number: NCT03111862.